Navigation Links
MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
Date:10/3/2007

c antibiotics as a consequence of its mechanism of action.

About Diabetes and Diabetic Foot Infection According to the U.S. Centers for Disease Control and Prevention (CDC), there are about 20.8 million people with diabetes in the U.S. (in 2005). Current estimates are that about 7% of all Americans have diabetes, and that prevalence is expected to increase each year. Among the complications caused by diabetes are foot disorders. It is estimated that up to about 25% of persons with diabetes will develop a foot ulcer in their lifetime of which about 60% get infected. Diabetic foot ulcers generally result from the consequences of peripheral neuropathy, with loss of protective sensations and foot deformities. The presence of peripheral vascular disease, increased biomechanical stress and acute trauma further increase the risk of foot ulcers. It usually takes several months for an ulcer to heal, and during this period there is a continual risk of foot infection. Infected foot ulcers can result in bone infection (osteomyelitis) or progressive gangrene, and are the major immediate cause of lower limb amputation. Diabetes is now the top cause of non-traumatic leg amputations in the developed world. Furthermore, foot ulcers are now the most frequent cause of diabetes-related hospitalizations. Thus, diabetic foot ulcers and infection are a major burden to both the patient and the healthcare system resulting in long-term disabilities and high demands on the healthcare system.

About MacroChem

MacroChem Corporation is a specialty pharmaceutical company that develops and seeks to commercialize pharmaceutical products. Currently, our portfolio of proprietary product candidates is based on our drug delivery technologies: SEPA(R), MacroDerm(TM) and DermaPass(TM). Our lead product candidate is EcoNail(TM), a topically applied SEPA-based econazole lacquer for the treatment of onychomycosis, a condition commonly known as nail fungus. Our other clinical stage product c
'/>"/>

SOURCE MacroChem Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
2. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug, AN2690; Findings Published in Science
3. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
4. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
5. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
6. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
7. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
8. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
9. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
10. Encouraging Clinical Activity of GSKs Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
11. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)...  Hospira, Inc. (NYSE: HSP ), ... infusion technologies, today reported results for the second ... the quarter were $1.1 billion and adjusted* diluted ... specified items as described later in this press ... Generally Accepted Accounting Principles (GAAP) basis, second-quarter 2014 ...
(Date:7/30/2014)... SAN ANTONIO , July 30, 2014 /PRNewswire/ ... technology company focused on innovating lifesaving devices and ... closed $4.5 million in Series A financing, which ... .  Proceeds from the deal will allow Bluegrass ... Inside-Out Access Catheter System, enhance manufacturing capabilities, and ...
(Date:7/30/2014)... , July 30, 2014  PDL BioPharma, Inc. (PDL) ... management will participate in the Jefferies 2014 Boston Healthcare ... Massachusetts. The conference will occur on August 6, 2014 and ... Inc. PDL BioPharma manages a portfolio of ... et al. antibody humanization patents and license agreements with ...
Breaking Medicine Technology:Hospira Reports Second-Quarter 2014 Results 2Hospira Reports Second-Quarter 2014 Results 3Hospira Reports Second-Quarter 2014 Results 4Hospira Reports Second-Quarter 2014 Results 5Hospira Reports Second-Quarter 2014 Results 6Hospira Reports Second-Quarter 2014 Results 7Hospira Reports Second-Quarter 2014 Results 8Hospira Reports Second-Quarter 2014 Results 9Hospira Reports Second-Quarter 2014 Results 10Hospira Reports Second-Quarter 2014 Results 11Hospira Reports Second-Quarter 2014 Results 12Hospira Reports Second-Quarter 2014 Results 13Hospira Reports Second-Quarter 2014 Results 14Hospira Reports Second-Quarter 2014 Results 15Hospira Reports Second-Quarter 2014 Results 16Hospira Reports Second-Quarter 2014 Results 17Hospira Reports Second-Quarter 2014 Results 18Hospira Reports Second-Quarter 2014 Results 19Hospira Reports Second-Quarter 2014 Results 20Hospira Reports Second-Quarter 2014 Results 21Hospira Reports Second-Quarter 2014 Results 22Hospira Reports Second-Quarter 2014 Results 23Hospira Reports Second-Quarter 2014 Results 24Hospira Reports Second-Quarter 2014 Results 25Hospira Reports Second-Quarter 2014 Results 26Hospira Reports Second-Quarter 2014 Results 27Hospira Reports Second-Quarter 2014 Results 28Hospira Reports Second-Quarter 2014 Results 29Hospira Reports Second-Quarter 2014 Results 30Hospira Reports Second-Quarter 2014 Results 31Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2
... Dec. 14 Cardinal Health today announced that executives of the ... Goldman Sachs CEO Unplugged Conference on Jan. 6 at Noon ... 28th Annual J.P. Morgan Healthcare Conference on Jan. 12 ... Francisco. , At these events, company executives will discuss Cardinal ...
... , STAMFORD, Conn., Dec. 14 Zargis ... SPDE ) and a spin-off from Siemens Corporate Research (NYSE: ... selling its award-winning Zargis Cardioscan(TM) system on Amazon.com, America,s largest ... were jointly named Popular Science magazine,s ...
Cached Medicine Technology:Cardinal Health Executives to Speak at Two Investor Events in January 2Zargis Cardioscan 'The Intelligent Stethoscope' Now Available on Amazon.com 2
(Date:7/30/2014)... Ticket Down is a reputable source for ... friendly exhibition match at the Red Bull Arena in ... that was left standing as the best team in the ... largest football competition and even embarrassed the host nation Brazilian ... Germany was led by seven players that called Bayern Munich ...
(Date:7/30/2014)... Church, VA (PRWEB) July 30, 2014 ... , Understanding Advanced Critical Thinking Skills and Innovative ... **Presented by Immel Resources and FDAnews**, Sept. 17-18, ... CAPA has been the #1 reason for 483 ... makes it clear: Developing a successful CAPA program ...
(Date:7/30/2014)... education in sub-Saharan Africa is being revitalized and ... increasing enrollment, broadening curricula, upgrading Internet access and ... , In the first substantial publication by participants ... (MEPI), more than 225 authors detailed progress being ... in a supplement being published today by the ...
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... year in the United States, at least 2,000 Americans die ... said Wednesday. Heat waves, heat stroke or sun stroke ... between 2006 and 2010, according to the U.S. Centers for ... a severe loss of body heat -- accounted for 63 ...
Breaking Medicine News(10 mins):Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 2Health News:Bayern Munich vs. Chivas Guadalajara Tickets Red Bull Arena: Ticket Down Slashes Ticket Prices for Chivas Guadalajara vs. Bayern Munich in Harrison, NJ 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Journal supplement details progress in African medical education 2Health News:Journal supplement details progress in African medical education 3Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3
... therapy where a radioactive source is placed in or just ... to be cancerous. The traditional// external beam radiation therapy ... the tumor, outside the body of a person. ... left in place either temporarily or permanently. For this purpose ...
... James Reilly, former president of the Irish Medical Organization (IMO) ... Election for Fine Gael// . Previously, Nora Owen, the party’s ... contestant is seeking the nomination in the Dublin North constituency ... selection convention, to be held on the 2nd of May. ...
... reliability of implanted cardiac pacemakers and defibrillators having improved ... malfunction// at times. ,For the thousands of ... reliability of these devices is an important issue. The ... whereas the defibrillator delivers a shock to restart a ...
... during older age results in grave consequences. People who ... through diet and exercise. This increases their physical function// ... lead to a loss of functional independence in the ... Dennis T. Villareal from Washington University School of Medicine ...
... Bolivar University in Caracas found that Lactobacillus casei (L ... flatulence capacity// and increased the nutritional value. Beans are ... the developing countries. ,Marisela Granito led the ... beans but not compromising on the nutritional value. The ...
... 60 and younger have an increased susceptibility to depression ... of the study are especially significant when considering// health-care ... patients who don't become depressed. The results of the ... of the Archives of Internal Medicine. ,According ...
Cached Medicine News:Health News:Brachytherapy Shows Promise for Cancer Treatment 2Health News:Reliability of Pacemakers and Defibrillators to be Improved 2Health News:Depression Accompanies Heart Attacks in Younger Women 2
Liquid, ready-to-use, bar-coded Olympus reagents are convenient, economical easy-to-use and reliable. This is one of 122 tests standardized for use on the Olympus AU400e, AU640e, AU2700, and AU5400 C...
The pediatric blanket provides full coverage for pediatric patient care. The generous size and versatility of these blankets include extra material for the shoulders and feet. The foot drape also red...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The design of the large pediatric underbody blanket conveniently warms the large child or small adult patient while allowing full access for surgeons and staff....
Medicine Products: